Back

OmniBind: Proteome-Wide Promiscuity Predictions for Early-Stage Drug Screening

Hanke, J.; Pujalte Ojeda, S.; Cheong, R. W.; Glasstetter, L. M.; Baker, E.; Lam, H. Y. I.; Brezinova, M.; Louet, A. A. B.; Zhang, S.; Vendruscolo, M.

2026-03-18 molecular biology
10.64898/2026.03.17.712433 bioRxiv
Show abstract

Off-target binding remains a leading cause of drug attrition, yet no method exists for rapidly quantifying small-molecule promiscuity across the human proteome. Here, we define promiscuity as the mean predicted binding affinity over 15,405 human proteins and derive a specificity score combining target affinity with this proteome-wide distribution. To make this assessment tractable at scale, we introduce OmniBind, a message-passing neural network that predicts promiscuity directly from a SMILES string at about a thousand compounds per second, several orders of magnitude faster than proteome-wide profiling. OmniBind promiscuity scores correlate with experimental binding data near assay reproducibility limits. Ranking candidates by specificity rather than affinity alone improves enrichment of approved drugs across all thresholds tested, an advantage robust to the choice of affinity predictor. OmniBind fills an unoccupied niche in the early-stage screening landscape as a fast, proteome-scale complement to traditional safety panels, with accuracy that will scale as the underlying affinity predictors continue to improve.

Matching journals

The top 6 journals account for 50% of the predicted probability mass.

50% of probability mass above

"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.